On 9 August 2024, MSD and Curon Biopharmaceutical announced the MSD acquisition of Curon developed CD3xCD19 bispecific antibody CN201, currently in Ph I/II trials for the treatment of B-cell associated diseases. Under the agreement, MSD will make an upfront payment of $700 million and milestone payments of up to $600 million for the development and regulatory approval of CN201. The transaction is expected to close in the third quarter of 2024.
This comes after MSD’s announcement earlier in the week of an expansion to its agreement with Daiichi Sankyo for the development and commercialisation of various cancer drugs.